{"id":84043,"topic":"peptides","source":"BioBuzz","title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","url_hash":"0f5fa649b16f744a54d96449cbc417c3a130b1fc","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5\" target=\"_blank\">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioBuzz</font>","content":null,"image_url":null,"lang":"en","published_at":"2026-09-16T14:11:57+00:00","fetched_at":"2026-09-16T21:15:09+00:00","status":"read","starred":0,"extract_state":"failed","summary_auto":null,"cluster_id":null,"extract_retries":2,"extract_error":"trafilatura_none","contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":545,"usable_text_length":545,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":545}},"news_item":{"id":84043,"canonical_url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","source_url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","source_name":"BioBuzz","author":null,"published_at":"2026-09-16T14:11:57+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5\" target=\"_blank\">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioBuzz</font>","full_text":null,"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5\" target=\"_blank\">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioBuzz</font>","extraction":{"state":"failed","confidence":0.2,"error":"trafilatura_none","explanation":"Low confidence: extractor returned no usable article text.","diagnostics_url":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":545,"usable_text_length":545,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":545}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","summary":"<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5\" target=\"_blank\">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioBuzz</font>","source":"BioBuzz","date":"2026-09-16T14:11:57+00:00","content":"","confidence":0.2,"diagnostics_url":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","quality_bucket":"low","failure_kind":"extractor_empty","retryable":false,"quality_reason":"Low confidence: extractor returned no usable article text.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":545,"usable_text_length":545,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":545}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/84043","export_markdown":"/api/items/84043/export?format=markdown","export_json":"/api/items/84043/export?format=json","diagnose":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/"},"formats":{"full":{"id":84043,"title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","source":"BioBuzz","author":null,"published_at":"2026-09-16T14:11:57+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5\" target=\"_blank\">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioBuzz</font>","full_text":null,"reading_time_min":1,"extraction":{"state":"failed","confidence":0.2,"error":"trafilatura_none","explanation":"Low confidence: extractor returned no usable article text.","diagnostics_url":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":545,"usable_text_length":545,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":545}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":545,"usable_text_length":545,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":545}},"actions":{"read":"/item/84043","export_markdown":"/api/items/84043/export?format=markdown","export_json":"/api/items/84043/export?format=json","diagnose":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/"}},"digest":{"id":84043,"title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","source":"BioBuzz","topic":"peptides","published_at":"2026-09-16T14:11:57+00:00","excerpt":"<a…","quality_bucket":"low","quality_reason":"Low confidence: extractor returned no usable article text.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","subtitle":"BioBuzz · 2026-09-16","summary":"<a…","badges":["quality:low","issue:extractor_empty"],"links":{"read":"/item/84043","original":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","diagnose":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/"},"quality_warning":"Low confidence: extractor returned no usable article text."},"export":{"title":"Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes - BioBuzz","url":"https://biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","summary":"<a href=\"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR2RQYnJvSk10YlhQU2MzWGd0Z21YT2xmQkxhSmxuZmRzYTJBT3I5ZGU1UklLNWU0THZWUVh3NGFmMUZYem4wOEs1ZmQ1MlphaTdta3BtSGVTQnZ2a1d5Xy1FYWhya255M19mS3Q1LW5mTUdfX0ZxQXdQam8wWkkyMVFaX3g4LXZRRndPOFVfUm05WTlFQnJWZzNuZ1pYTlYtUnN6V2RnTEVEa3FmRWRwYUEySGdOTU5RUVl4cFhMczNQVm1DZ25vNVExenJhejRjVnRxNTJnNEV5cl9nWUE?oc=5\" target=\"_blank\">Elvinix Licenses Zealand Pharma's Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioBuzz</font>","source":"BioBuzz","date":"2026-09-16T14:11:57+00:00","content":"","confidence":0.2,"diagnostics_url":"/api/diagnose?url=https%3A//biobuzz.io/news/elvinix-licenses-zealand-pharmas-dual-agonist-peptide-portfolio-to-chase-a-disease-modifying-therapy-for-type-1-diabetes/","quality_bucket":"low","failure_kind":"extractor_empty","retryable":false,"quality_reason":"Low confidence: extractor returned no usable article text.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":545,"usable_text_length":545,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":545}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}